+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Extensive gray matter volume reduction in treatment-resistant schizophrenia

Extensive gray matter volume reduction in treatment-resistant schizophrenia

International Journal of Neuropsychopharmacology 18(7): Pyv016

Approximately one-third of people with schizophrenia are treatment-resistant and some do not achieve remission with clozapine, the gold-standard antipsychotic medication for treatment-resistant schizophrenia. This study compared global and regional brain volumes between treatment-respondent and treatment-resistant patients with schizophrenia, including a group of patients who were clozapine-resistant. T1-weighted brain MRIs were obtained on a 3T scanner in 20 controls and 52 people with schizophrenia who were selected based on their symptomatic responses to antipsychotic medication: 18 responded well to first-line atypical antipsychotics (FLR), 19 were treatment-resistant but responsive to clozapine monotherapy (TR), and 15 were ultra-treatment-resistant and did not respond to clozapine (UTR). Treatment groups were matched for disease duration and current psychopathology. SIENAX and FSL-VBM were used to investigate differences in the global brain, gray matter (GM), white matter, ventricular cerebrospinal fluid volumes, and regional GM volumes. GM volume was significantly reduced in the TR and UTR groups compared with controls and the FLR group (p < 0.05). GM volume was significantly reduced in TR patients compared with FLRs in the superior, middle, and inferior temporal gyri, pre- and post-central gyri, middle and superior frontal gyri, right supramarginal gyrus, and right lateral occipital cortex. UTR patients showed reduced GM compared with FLRs in their right parietal operculum and left cerebellum. No significant volume differences were observed between TR and UTR groups. These differences are unlikely to be solely due to medication effects, and reduced GM volume in treatment-resistant schizophrenia may represent an accelerated disease course or a different underlying pathology.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057847350

Download citation: RISBibTeXText

PMID: 25716781

DOI: 10.1093/ijnp/pyv016

Related references

Prefrontal gray matter volume reduction in first episode schizophrenia. Cerebral Cortex 11(4): 374-381, 2001

Extensive Gray Matter Volume Reduction and Correlations with Neuropsychological Performance in Alcohol Use Disorder Patients. Bulletin of Clinical Psychopharmacology 26(4): 355-363, 2016

Gray matter volume reduction in rostral middle frontal gyrus in patients with chronic schizophrenia. Schizophrenia Research 123(2-3): 153-159, 2010

Gray matter volume differences and the effects of smoking on gray matter in schizophrenia. Schizophrenia Research 97(1-3): 242-249, 2007

Volume reduction of the left planum temporale gray matter associated with long duration of untreated psychosis in schizophrenia: a preliminary report. Psychiatry Research 154(3): 209-219, 2007

Longitudinal gray-matter volume change in the default-mode network: utility of volume standardized with global gray-matter volume for Alzheimer's disease: a preliminary study. Radiological Physics and Technology 8(1): 64-72, 2015

Duration of untreated psychosis is associated with temporal and occipitotemporal gray matter volume decrease in treatment naïve schizophrenia. Plos one 8(12): E83679, 2013

Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiatry Research 131(1): 45-56, 2004

Cortical thickness, gray matter volume, and white matter anisotropy and diffusivity in schizophrenia. Neuroradiology 53(11): 859-866, 2011

Cortical thickness, gray matter volume, and white matter anisotropy and diffusivity in schizophrenia. Yearbook of Psychiatry and Applied Mental Health 2013: 387-388, 2013

Genome-wide association analysis with gray matter volume as a quantitative phenotype in first-episode treatment-naïve patients with schizophrenia. Plos one 8(9): E75083, 2013

Hippocampal and orbital inferior frontal gray matter volume abnormalities and cognitive deficit in treatment-naive, first-episode patients with schizophrenia. Schizophrenia Research 152(2-3): 339-343, 2014

Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. Biological Psychiatry 63(5): 465-474, 2008

Morphological changes in gray matter volume correlate with catechol-O-methyl transferase gene Val158Met polymorphism in first-episode treatment-naïve patients with schizophrenia. Neuroscience Bulletin 31(1): 31-42, 2015

Volume changes in gray matter in patients with schizophrenia. American Journal of Psychiatry 159(2): 244-250, 2002